These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19335936)

  • 21. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information.
    Ranganathan M; Radhakrishnan R; Addy PH; Schnakenberg-Martin AM; Williams AH; Carbuto M; Elander J; Pittman B; Andrew Sewell R; Skosnik PD; D'Souza DC
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):176-183. PubMed ID: 28642081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis.
    Bhattacharyya S; Atakan Z; Martin-Santos R; Crippa JA; Kambeitz J; Malhi S; Giampietro V; Williams S; Brammer M; Rubia K; Collier DA; McGuire PK
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):26-37. PubMed ID: 25532865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).
    Bassir Nia A; Orejarena MJ; Flynn L; Luddy C; D'Souza DC; Skosnik PD; Pittman B; Ranganathan M
    Psychopharmacology (Berl); 2022 May; 239(5):1621-1628. PubMed ID: 35438304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.
    Ranganathan M; Carbuto M; Braley G; Elander J; Perry E; Pittman B; Radhakrishnan R; Sewell RA; D'Souza DC
    Int J Neuropsychopharmacol; 2012 Oct; 15(9):1251-64. PubMed ID: 22243563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.
    Müller-Vahl KR; Koblenz A; Jöbges M; Kolbe H; Emrich HM; Schneider U
    Pharmacopsychiatry; 2001 Jan; 34(1):19-24. PubMed ID: 11229617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.
    Cortes-Briones J; Skosnik PD; Mathalon D; Cahill J; Pittman B; Williams A; Sewell RA; Ranganathan M; Roach B; Ford J; D'Souza DC
    Neuropsychopharmacology; 2015 Aug; 40(9):2124-34. PubMed ID: 25709097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition.
    Henquet C; Rosa A; Krabbendam L; Papiol S; Fananás L; Drukker M; Ramaekers JG; van Os J
    Neuropsychopharmacology; 2006 Dec; 31(12):2748-57. PubMed ID: 16936704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study.
    Barkus E; Morrison PD; Vuletic D; Dickson JC; Ell PJ; Pilowsky LS; Brenneisen R; Holt DW; Powell J; Kapur S; Murray RM
    J Psychopharmacol; 2011 Nov; 25(11):1462-8. PubMed ID: 20851843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.
    Mathai DS; Holst M; Rodgman C; Haile CN; Keller J; Hussain MZ; Kosten TR; Newton TF; Verrico CD
    J Neuropsychiatry Clin Neurosci; 2018; 30(1):66-76. PubMed ID: 28641496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.
    Bhattacharyya S; Crippa JA; Allen P; Martin-Santos R; Borgwardt S; Fusar-Poli P; Rubia K; Kambeitz J; O'Carroll C; Seal ML; Giampietro V; Brammer M; Zuardi AW; Atakan Z; McGuire PK
    Arch Gen Psychiatry; 2012 Jan; 69(1):27-36. PubMed ID: 22213786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
    Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
    Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis.
    Colizzi M; Weltens N; McGuire P; Lythgoe D; Williams S; Van Oudenhove L; Bhattacharyya S
    Mol Psychiatry; 2020 Dec; 25(12):3231-3240. PubMed ID: 30770892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.
    D'Souza DC; Braley G; Blaise R; Vendetti M; Oliver S; Pittman B; Ranganathan M; Bhakta S; Zimolo Z; Cooper T; Perry E
    Psychopharmacology (Berl); 2008 Jul; 198(4):587-603. PubMed ID: 18228005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users.
    Ramaekers JG; Theunissen EL; de Brouwer M; Toennes SW; Moeller MR; Kauert G
    Psychopharmacology (Berl); 2011 Mar; 214(2):391-401. PubMed ID: 21049267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?
    Curran HV; Hindocha C; Morgan CJA; Shaban N; Das RK; Freeman TP
    Psychol Med; 2019 Jul; 49(9):1574-1580. PubMed ID: 30176957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.
    Bonnet U; Borda T; Scherbaum N; Specka M
    Drug Alcohol Depend; 2015 Oct; 155():302-6. PubMed ID: 26298553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabinoid Modulation of Frontolimbic Activation and Connectivity During Volitional Regulation of Negative Affect.
    Gorka SM; Phan KL; Lyons M; Mori S; Angstadt M; Rabinak CA
    Neuropsychopharmacology; 2016 Jun; 41(7):1888-96. PubMed ID: 26647971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.